FDA approves TherMatrx' microwave BPH (benign prostatic hyperplasia) therapy:
This article was originally published in Clinica
The US FDA has approved for sale TherMatrx' TMx-2000 transurethral microwave thermotherapy device for benign prostatic hyperplasia (BPH). Results from a three-year, 200-patient trial of the device showed that it achieved highly significant improvements in patient symptoms, with minimal side effects. TherMatrx is based in Chicago, Illinois.